Drugs targeting the mitochondrial pore act as citotoxic and cytostatic agents in temozolomide-resistant glioma cells

<p>Abstract</p> <p>Background</p> <p>High grade gliomas are one of the most difficult cancers to treat and despite surgery, radiotherapy and temozolomide-based chemotherapy, the prognosis of glioma patients is poor. Resistance to temozolomide is the major barrier to effective therapy. Alternative therapeutic approaches have been shown to be ineffective for the treatment of genetically unselected glioma patients. Thus, novel therapies are needed. Mitochondria-directed chemotherapy is an emerging tool to combat cancer, and inner mitochondrial permeability transition (MPT) represents a target for the development of cytotoxic drugs. A number of agents are able to induce MPT and some of them target MPT-pore (MPTP) components that are selectively up-regulated in cancer, making these agents putative cancer cell-specific drugs.</p> <p>Objective</p> <p>The aim of this paper is to report a comprehensive analysis of the effects produced by selected MPT-inducing drugs (Betulinic Acid, Lonidamine, CD437) in a temozolomide-resistant glioblastoma cell line (ADF cells).</p> <p>Methods</p> <p>EGFRvIII expression has been assayed by RT-PCR. EGFR amplification and PTEN deletion have been assayed by differential-PCR. Drugs effect on cell viability has been tested by crystal violet assay. MPT has been tested by JC1 staining. Drug cytostatic effect has been tested by mitotic index analysis. Drug cytotoxic effect has been tested by calcein AM staining. Apoptosis has been assayed by Hoechst incorporation and Annexine V binding assay. Authophagy has been tested by acridine orange staining.</p> <p>Results</p> <p>We performed a molecular and genetic characterization of ADF cells and demonstrated that this line does not express the EGFRvIII and does not show EGFR amplification. ADF cells do not show PTEN mutation but differential PCR data indicate a hemizygous deletion of PTEN gene. We analyzed the response of ADF cells to Betulinic Acid, Lonidamine, and CD437. Our data demonstrate that MPT-inducing agents produce concentration-dependent cytostatic and cytotoxic effects in parallel with MPT induction triggered through MPTP. CD437, Lonidamine and Betulinic acid trigger apoptosis as principal death modality.</p> <p>Conclusion</p> <p>The obtained data suggest that these pharmacological agents could be selected as adjuvant drugs for the treatment of high grade astrocytomas that resist conventional therapies or that do not show any peculiar genetic alteration that can be targeted by specific drugs.</p

FP678IMPACT OF EUROPEAN MEDICINES AGENCY RECOMMENDATIONS FOR ALLERGIC REACTIONS TO INTRAVENOUS IRON-CONTAINING DRUGS IN DIALYSIS CENTERS OF LOMBARDY REGION

n/

The new generation hdhodh inhibitor meds433 hinders the in vitro replication of sars-cov-2 and other human coronaviruses

Although coronaviruses (CoVs) have long been predicted to cause zoonotic diseases and pandemics with high probability, the lack of effective anti-pan-CoVs drugs rapidly usable against the emerging SARS-CoV-2 actually prevented a promptly therapeutic intervention for COVID-19. Development of host-targeting antivirals could be an alternative strategy for the control of emerging CoVs infections, as they could be quickly repositioned from one pandemic event to another. To contribute to these pandemic preparedness efforts, here we report on the broad-spectrum CoVs antiviral activity of MEDS433, a new inhibitor of the human dihydroorotate dehydrogenase (hDHODH), a key cellular enzyme of the de novo pyrimidine biosynthesis pathway. MEDS433 in-hibited the in vitro replication of hCoV-OC43 and hCoV-229E, as well as of SARS-CoV-2, at low nanomolar range. Notably, the anti-SARS-CoV-2 activity of MEDS433 against SARS-CoV-2 was also observed in kidney organoids generated from human embryonic stem cells. Then, the antiviral activity of MEDS433 was reversed by the addition of exogenous uridine or the product of hDHODH, the orotate, thus confirming hDHODH as the specific target of MEDS433 in hCoVs-infected cells. Taken together, these findings suggest MEDS433 as a potential candidate to develop novel drugs for COVID-19, as well as broad-spectrum antiviral agents exploitable for future CoVs threats

Aquaporins Are One of the Critical Factors in the Disruption of the Skin Barrier in Inflammatory Skin Diseases

The skin is the largest organ of the human body, serving as an effective mechanical barrier between the internal milieu and the external environment. The skin is widely considered the first-line defence of the body, with an essential function in rejecting pathogens and preventing mechanical, chemical, and physical damages. Keratinocytes are the predominant cells of the outer skin layer, the epidermis, which acts as a mechanical and water-permeability barrier. The epidermis is a permanently renewed tissue where undifferentiated keratinocytes located at the basal layer proliferate and migrate to the overlying layers. During this migration process, keratinocytes undertake a differentiation program known as keratinization process. Dysregulation of this differentiation process can result in a series of skin disorders. In this context, aquaporins (AQPs), a family of membrane channel proteins allowing the movement of water and small neutral solutes, are emerging as important players in skin physiology and skin diseases. Here, we review the role of AQPs in skin keratinization, hydration, keratinocytes proliferation, water retention, barrier repair, wound healing, and immune response activation. We also discuss the dysregulated involvement of AQPs in some common inflammatory dermatological diseases characterised by skin barrier disruption.This work was supported by a Biomolecular Analyses for Tailored Medicine in AcneiNversa (BATMAN) project, funded by ERA PerMed (JTC_2018) to S.C.; by a Starting Grant (SG- 2019-12369421) funded by Italian Ministry of Health to P.M.T.; by two grants, from the Italian Ministry of University and Research (MUR) “Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale 2017” (PRIN2017 # 2017J92TM5) and “Fondo Integrativo Speciale per la Ricerca 2020” (FISR 2020 CoVAPin # FISR2020IP_04051), to Giuseppe Calamita; and a grant from the University of Bari “Horizon Europe Seeds 2022-2023” (Uniba Euroseeds #S10) to Giuseppe Calamita

Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis

We analyzed whether serum albumin is independently associated with portal vein thrombosis (PVT) in liver cirrhosis (LC) and if a biologic plausibility exists. This study was divided into three parts. In part 1 (retrospective analysis), 753 consecutive patients with LC with ultrasound-detected PVT were retrospectively analyzed. In part 2, 112 patients with LC and 56 matched controls were entered in the cross-sectional study. In part 3, 5 patients with cirrhosis were entered in the in vivo study and 4 healthy subjects (HSs) were entered in the in vitro study to explore if albumin may affect platelet activation by modulating oxidative stress. In the 753 patients with LC, the prevalence of PVT was 16.7%; logistic analysis showed that only age (odds ratio [OR], 1.024; P = 0.012) and serum albumin (OR, -0.422; P = 0.0001) significantly predicted patients with PVT. Analyzing the 112 patients with LC and controls, soluble clusters of differentiation (CD)40-ligand (P = 0.0238), soluble Nox2-derived peptide (sNox2-dp; P &lt; 0.0001), and urinary excretion of isoprostanes (P = 0.0078) were higher in patients with LC. In LC, albumin was correlated with sCD4OL (Spearman's rank correlation coefficient [r(s)], -0.33; P &lt; 0.001), sNox2-dp (r(s), -0.57; P &lt; 0.0001), and urinary excretion of isoprostanes (r(s), -0.48; P &lt; 0.0001) levels. The in vivo study showed a progressive decrease in platelet aggregation, sNox2-dp, and urinary 8-iso prostaglandin F2 alpha-III formation 2 hours and 3 days after albumin infusion. Finally, platelet aggregation, sNox2-dp, and isoprostane formation significantly decreased in platelets from HSs incubated with scalar concentrations of albumin. Conclusion: Low serum albumin in LC is associated with PVT, suggesting that albumin could be a modulator of the hemostatic system through interference with mechanisms regulating platelet activation

The “Diabetes Comorbidome”: A Different Way for Health Professionals to Approach the Comorbidity Burden of Diabetes

(1) Background: The disease burden related to diabetes is increasing greatly, particularly in older subjects. A more comprehensive approach towards the assessment and management of diabetes’ comorbidities is necessary. The aim of this study was to implement our previous data identifying and representing the prevalence of the comorbidities, their association with mortality, and the strength of their relationship in hospitalized elderly patients with diabetes, developing, at the same time, a new graphic representation model of the comorbidome called “Diabetes Comorbidome”. (2) Methods: Data were collected from the RePoSi register. Comorbidities, socio-demographic data, severity and comorbidity indexes (Cumulative Illness rating Scale CIRS-SI and CIRS-CI), and functional status (Barthel Index), were recorded. Mortality rates were assessed in hospital and 3 and 12 months after discharge. (3) Results: Of the 4714 hospitalized elderly patients, 1378 had diabetes. The comorbidities distribution showed that arterial hypertension (57.1%), ischemic heart disease (31.4%), chronic renal failure (28.8%), atrial fibrillation (25.6%), and COPD (22.7%), were the more frequent in subjects with diabetes. The graphic comorbidome showed that the strongest predictors of death at in hospital and at the 3-month follow-up were dementia and cancer. At the 1-year follow-up, cancer was the first comorbidity independently associated with mortality. (4) Conclusions: The “Diabetes Comorbidome” represents the perfect instrument for determining the prevalence of comorbidities and the strength of their relationship with risk of death, as well as the need for an effective treatment for improving clinical outcomes

Antidiabetic Drug Prescription Pattern in Hospitalized Older Patients with Diabetes

Objective: To describe the prescription pattern of antidiabetic and cardiovascular drugs in a cohort of hospitalized older patients with diabetes. Methods: Patients with diabetes aged 65 years or older hospitalized in internal medicine and/or geriatric wards throughout Italy and enrolled in the REPOSI (REgistro POliterapuie SIMI—Società Italiana di Medicina Interna) registry from 2010 to 2019 and discharged alive were included. Results: Among 1703 patients with diabetes, 1433 (84.2%) were on treatment with at least one antidiabetic drug at hospital admission, mainly prescribed as monotherapy with insulin (28.3%) or metformin (19.2%). The proportion of treated patients decreased at discharge (N = 1309, 76.9%), with a significant reduction over time. Among those prescribed, the proportion of those with insulin alone increased over time (p = 0.0066), while the proportion of those prescribed sulfonylureas decreased (p &lt; 0.0001). Among patients receiving antidiabetic therapy at discharge, 1063 (81.2%) were also prescribed cardiovascular drugs, mainly with an antihypertensive drug alone or in combination (N = 777, 73.1%). Conclusion: The management of older patients with diabetes in a hospital setting is often sub-optimal, as shown by the increasing trend in insulin at discharge, even if an overall improvement has been highlighted by the prevalent decrease in sulfonylureas prescription

Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both

Background and objective: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) mutually increase the risk of being present in the same patient, especially if older. Whether or not this coexistence may be associated with a worse prognosis is debated. Therefore, employing data derived from the REPOSI register, we evaluated the clinical features and outcomes in a population of elderly patients admitted to internal medicine wards and having COPD, HF or COPD + HF. Methods: We measured socio-demographic and anthropometric characteristics, severity and prevalence of comorbidities, clinical and laboratory features during hospitalization, mood disorders, functional independence, drug prescriptions and discharge destination. The primary study outcome was the risk of death. Results: We considered 2,343 elderly hospitalized patients (median age 81 years), of whom 1,154 (49%) had COPD, 813 (35%) HF, and 376 (16%) COPD + HF. Patients with COPD + HF had different characteristics than those with COPD or HF, such as a higher prevalence of previous hospitalizations, comorbidities (especially chronic kidney disease), higher respiratory rate at admission and number of prescribed drugs. Patients with COPD + HF (hazard ratio HR 1.74, 95% confidence intervals CI 1.16-2.61) and patients with dementia (HR 1.75, 95% CI 1.06-2.90) had a higher risk of death at one year. The Kaplan-Meier curves showed a higher mortality risk in the group of patients with COPD + HF for all causes (p = 0.010), respiratory causes (p = 0.006), cardiovascular causes (p = 0.046) and respiratory plus cardiovascular causes (p = 0.009). Conclusion: In this real-life cohort of hospitalized elderly patients, the coexistence of COPD and HF significantly worsened prognosis at one year. This finding may help to better define the care needs of this population

STUDIO DEL RUOLO DI ISOFORME DELLA PROTEINA ANT NEI PROCESSI DI PROLIFERAZIONE / MORTE CELLULARE DELLE CELLULE DI GLIOBLASTOMA UMANE

I gliomi maligni, di cui fanno parte il glioblastoma multiforme e l’astrocitoma anaplastico, rappresentano i più comuni tumori primari del cervello e nonostante la resezione chirurgica, la radioterapia e la chemioterapia, la prognosi per i pazienti colpiti rimane infausta. Persiste quindi la necessità di trovare nuove terapie. Il mitocondrio, e le attività ad esso correlate, sono oggetto centrale di ricerche atte ad individuare nuove cure per diversi tipi di tumori. Esistono infatti molteplici differenze, relative al mitocondrio e al suo funzionamento, tra le cellule tumorali e le controparti normali. In questo contesto, questo lavoro di tesi si è concentrato sullo studio del ruolo della proteina mitocondriale ANT nella biologia delle cellule di glioma, soprattutto in vista delle sue rilevanti funzioni sia nel metabolismo cellulare che nella regolazione dei processi di morte. La proteina ANT, oltre al suo principale ruolo di trasportatore di nucleotidi adeninici a cavallo della membrana mitocondriale interna, ha anche un ruolo chiave sia nella formazione e nella regolazione del poro di transizione della permeabilità mitocondriale (PTPC), che nella conduttanza protonica come proteina disaccoppiante della catena di trasporto degli elettroni. Nell’uomo si conoscono quattro isoforme della proteina ANT. La loro espressione dipende sia dallo stadio di sviluppo che dal tipo di tessuto. In particolare ANT1 è altamente espressa nei tessuti differenziati mentre ANT2 è prevalentemente espressa nelle cellule indifferenziate e nei tumori. Il sistema modello utilizzato in questo studio è la linea cellulare ADF di glioblastoma multiforme umano, cellule altamente aggressive e resistenti alle terapie standard attualmente in uso. In questo lavoro abbiamo inoltre dimostrato che, sebbene le cellule ADF hanno una catena di trasporto degli elettroni parzialmente attiva, esse utilizzano quasi esclusivamente la glicolisi per produrre ATP. Mediante studi di RT-PCR e real-time RT-PCR abbiamo dimostrato che queste cellule esprimono le isoforme ANT1 e 2 e che l’ isoforma 2 è predominante rispetto alla 1. Mediante i nostri studi di interferenza genica abbiamo dimostrato che, nonostante ANT2 sia 5 volte più abbondante di ANT1, il suo silenziamento o la sua sovraespressione non hanno effetti sulla vitalità cellulare. Invece, il silenziamento di ANT1 provoca una drastica riduzione della vitalità cellulare mediante l’induzione di morte apoptotica. Mediante l’utilizzo di inibitori della funzione di co-trasporto dei nucleotidi adeninici abbiamo dimostrato che l’effetto del silenziamento di ANT1 sulla vitalità cellulare è indipendente dal suo ruolo di trasportatore. Inoltre l’utilizzo dell’inibitore dell’ apertura del PTPC ha permesso di dimostrare che l’effetto del silenziamento di ANT1 è anche indipendente dal suo coinvolgimento nella formazione e regolazione del PTPC. Studi sulla stabilità delle membrane lisosomiali, saggi dose-risposta al trattamento con pro-ossidanti e la quantificazione del glucosio consumato ci hanno permesso di intuire che, quando la proteina ANT viene silenziata, le cellule ADF sono sottoposte a stress ossidativo. Ciò ci permette di ipotizzare che la riduzione della vitalità prodotta dal silenziamento di ANT1 sia dovuta ad un aumento di ROS mitocondriali causato dalla perdita della funzione di ANT1 come proteina disaccoppiante. La riduzione della funzione disaccoppiante potrebbe infatti giocare un ruolo chiave nelle cellule ADF dove, data l’assenza di fosforilazione ossidativa, la riduzione della conduttanza basale (operata specificamente dalla l’isoforma ANT1) potrebbe comportare un aumento significativo del potenziale transmembrana mitocondriale il cui valore è direttamente dipendente alla produzione di ROS. Questi ritrovamenti suggeriscono che in cellule di glioma con metabolismo preferenzialmente glicolitico, recentemente ritenute le principali responsabili della invasività dei tumori cerebrali, la riduzione dei livelli di ANT1 potrebbe rappresentare una potenziale strategia terapeutica